HEИндивидуална стипендия2023–2025

ALIVE · Analytical platform for non-invasive diagnosis of LIVEr disease

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период: 2023-04-01 → 2025-03-31
Финансиране от ЕС: 187 624 €
Участници: 2
Схема: HORIZON-TMA-MSCA-PF-EF

Линиите свързват координатора с партньорите.

Накратко на български

Вънколетъчните везикули, които пренасят биомолекули между клетките, се анализират чрез нов чип за по-лесно откриване на заболявания като тези на черния дроб. Това помага за създаването на по-точни и достъпни методи за диагностика чрез кръвни изследвания.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Analytical platform for non-invasive diagnosis of LIVEr disease

The ALIVE project addressed the urgent need for more efficient, selective, and scalable methods for the separation and analysis of extracellular vesicles (EVs)-nanoscale carriers of biomolecules involved in cell-to-cell communication and promising biomarkers for disease diagnostics. Traditional techniques struggle to separate EVs from similar particles such as lipoproteins, particularly in clinical samples like blood plasma. ALIVE proposed an innovative electrophoretic strategy-depletion-zone isotachophoresis (dzITP), to fractionate EV subpopulations based on their electrophoretic mobility. Set against the backdrop of a growing demand for liquid biopsy tools, precision diagnostics, and affordable healthcare, the project aimed to develop a miniaturized, reusable chip platform capable of performing high-resolution EV separation. It combined electrokinetic technologies with mass spectrometry to enable lipidomic fingerprinting of EVs, offering new possibilities for disease biomarker discovery, particularly in liver-related disorders such as NAFLD. Through a series of proof-of-concept experiments, ALIVE demonstrated the capability of dzITP to separate EVs from lilpoproteins, protein and dye residues, as well as among EV subtypes. The integration of precise fraction retrieval methods, including electroosmotic flow control and segmented flow, opened avenues for downstream lipidomic profiling. The long-term goal is to translate this technology into a robust, scalable, and cost-effective diagnostic platform with direct applications in precision medicine and clinical research.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Non-alcoholic fatty liver disease (NAFLD) is a disease of alarmingly increasing prevalence, associated with metabolic and cardiovascular complications and morbid mortality. The disease spectrum covers from a simple steatosis to non-alcoholic steatohepatitis (NASH). With estimated 25% of population having NAFLD, it makes it the most common liver disease in the world. While diagnosing and stratifying NAFLD and NASH is of high priority to identify subjects with increased risk for cardio-vascular complications, the gold standard of current diagnostics is an invasive liver biopsy. Recently discovered extracellular vesicles (EVs) have shown high potential to become novel source of non-invasive biomarkers as they are loaded with the same molecular information as their parental cells (proteins, metabolites, RNAs). Molecular information of liver-derived EVs could be a great source of liver specific biomarkers, that are obtainable in circulation and are suitable for non-invasive diagnostics. However, analysing biochemical/omics profiles of tissue specific EVs in biofluids is an unsolved challenge and has not been realized in routine clinical diagnostics yet. In this project ALIVE we propose to develop a technology capable of isolating cell and organ specific EVs from biological samples and perform their omics analysis and to apply this technology in the proof-of-concept investigation of potential biomarkers of liver disease in blood. ALIVE is a great opportunity for the experience researcher Dr. Andrea Capuano to gain new technical and transferable skills, exchange knowledge with the host, an innovative European startup EXIT071 and secure a leadership position in innovative ecosystem of Europe.

Оригинален текст от CORDIS (на английски).

Участници

EXIT071 BV · LEIDENКоординаторНидерландия
UNIVERSITEIT LEIDEN · LeidenНидерландия